Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

Inclusion Criteria: * Pain or symptoms of CIPN of \>= 3 months duration, for which the patient wants intervention. * NOTE: Neurotoxic chemotherapy must have been completed \>= 6 months (186 days) prior to registration and there must be no further planned neurotoxic chemotherapy for \> 6 months after registration. * Tingling, numbness or pain was at least a four out of ten problem during the week prior to registration, on a 0-10 scale where zero was no problem and ten was the worst possible problem (patient verbal report to clinician). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2. * Negative pregnancy test done =\< 14 days prior to registration, for persons of childbearing potential only. * Provided written informed consent. * Ability to complete questionnaire(s) by themselves or with assistance. * Life expectancy \>= 6 months. Exclusion Criteria: * Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects: * Pregnant persons. * Nursing persons. * Persons of childbearing potential who are unwilling to employ adequate contraception. * Previous diagnosis of diabetic or other peripheral neuropathy. * Current or previous use of fingolimod. * History of the following preexisting conditions: ischemic heart disease, cardiac arrest, cerebrovascular disease, uncontrolled hypertension, symptomatic bradycardia, macular edema, recurrent syncope, severe untreated sleep apnea, herpes si…